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Abstract
Background and Aims: Cancer risk in inflammatory bowel disease [IBD] is still debated. In a prospective, 
multicentre, nested case-control study, we aimed to characterise incident cases of cancer in IBD. The role 
of immunomodulators vs clinical characteristics of IBD as risk factors for cancer was also investigated.
Materials and Methods: From January 2012 to December 2014, each IBD patient with incident 
cancer was matched with two IBD patients without cancer for: IBD type, gender, and age. Risk 
factors were assessed by multivariate regression analysis.
Results: IBD patients considered numbered 44 619: 21 953 Crohn’s disease [CD], 22 666 ulcerative 
colitis [UC]. Cancer occurred in 174 patients: 99 CD [CD-K], 75 UC [UC-K]. Controls included 198 CD 
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[CD-C], 150 UC [UC-C]. Cancer incidence in IBD was 3.9/1000, higher in CD (4.5/1000 [99/21,953]) than 
in UC (3.3/1000 [75/22,666]; p = 0.042). Cancers involved: digestive system [36.8%], skin [13.2%], 
urinary tract [12.1%], lung [8.6%], breast [8%], genital tract [6.9%], thyroid [4.6%], lymphoma [3.5%], 
others [6.3%]. In CD, penetrating behaviour and combined thiopurines and tumour necrosis factor 
alpha [TNFα] antagonists were risk factors for cancer overall: odds ratio [OR] (95% confidence 
interval [CI] 2.33 [1.01–5.47]); 1.97 [1.1–3.5]; and for extracolonic cancers 3.9 [1.56–10.1]; 2.15 [1.17–
4.1], respectively. In UC, risk factors were pancolitis and disease-related surgery for cancer overall 
(OR: 2.52 [1.26–5.1]; 5.09 [1.73–17.1]); disease-related surgery for colorectal cancer [CRC] (OR 3.6 
[1.0–12]); and extensive and left-sided vs distal UC for extracolonic cancers (OR: 2.55 [1.15–5.9]; 2.6 
[1.04–6.6]), respectively.
Conclusions: In a multicentre study, penetrating CD and extensive UC were risk factors for cancer 
overall. Cancer incidence was higher in CD than in UC.
Keywords:  Inflammatory bowel disease; cancer risk; phenotype
1. Introduction
Risk factors for cancer in inflammatory bowel disease [IBD] are 
still debated.1 Thiopurines [IS] have been reported to increase the 
risk of lymphoma1,2 and of non-melanoma skin cancers [NMSC], 
particularly in Crohn’s disease [CD].3,4 The cancer risk associated 
with tumour necrosis factor-α [TNFα] antagonists is undefined, 
due to the relatively short follow-up [first trial published in 1995] 
and to the frequently combined treatment with IS.5,6 Nevertheless, 
TNFα antagonists currently appear not to increase the risk of cancer 
overall, as supported by a multicentre case-control study in 2006.7,8  
and by several independent studies.1,9,10,11,12 An increased risk of 
melanoma has been reported using TNFα antagonists in IBD.13,14 
Hepatosplenic T-cell lymphoma [HSTCL] has been associated with 
thiopurine use, particularly in young male patients with CD, treated 
with combined TNFα antagonists.15,16 However, the absolute risk of 
these cancers appears to be low.
Recently, research has been focused on the cancer risk associated 
with IS and/or anti-TNFα treatments. Conversely, the role of clini-
cal characteristics of IBD in determining the cancer risk when using 
any immunomodulator [IMM] has been less extensively investi-
gated. In 2012, in a single-centre study we indicated penetrating CD 
and pancolitis in ulcerative colitis [UC] as significant risk factors for 
cancer overall.17 In 2013, a Danish study indicated CD phenotype 
as a risk factor for cancer.18 To the best of our knowledge, the role 
of clinical characteristics and phenotype of IBD in determining the 
cancer risk in relation to IMM treatments is currently undefined. 
This issue may assume relevance due to the frequent use of IMM 
in IBD, particularly in young patients with severe and chronically 
active disease.
In order to address these issues, we aimed to prospectively assess, 
in a multicentre nested case-control study, the incidence and charac-
teristics of cancer in a cohort of IBD patients followed up for 3 years. 
The role of clinical characteristics of IBD vs the use of thiopurines 
and/or TNFα antagonists in determining the incidence of cancer was 
also investigated.
2. Materials and Methods
2.1. Study design
In a prospective multicentre, nested case-control study, all incident 
cases of cancer diagnosed in 16 IBD referral centres from January 
1, 2012 to December 31, 2014 were recorded. All the units referred 
to the Italian Group for the study of Inflammatory Bowel Disease 
[IG-IBD]. In each of the 16 centres, each IBD patient with incident 
cancer/ neoplasia [IBD-K] was retrospectively matched with two 
IBD controls with no cancer [IBD-C] referring to the same IBD cen-
tre, for: IBD type [CD vs UC], gender, and age [± 5 years].
2.2. Study population
Inclusion criteria shared by IBD-K and IBD-C were:  1] diagnosis 
of CD or UC, defined according to current guidelines 5,6; 2] diagno-
sis of IBD ≥ 6 months; 3] regular follow-up [≥ two visits/year]; 4] 
age > 15 years; 5] no history of cancer; 6] clinical records includ-
ing characteristics of IBD and of cancer; and 7] informed consent. 
All incident cases of neoplasia and characteristics of patients were 
recorded in a shared database including: date of birth, age at time 
of last visit and at diagnosis of IBD and of cancer, IBD type [CD/
UC], CD extent [L1-L4],5,19 CD behaviour [B1-B3],5,19 perianal dis-
ease (yes/no [Y/N]), family history of IBD [Y/N], smoking [Y/N], 
extraintestinal manifestations [EIM][Y/N], disease-related surgery, 
current or past use of thiopurines [IS; azathioprine, AZA], TNFα 
antagonists, other IMM, date at first and last use of any IMM, and 
cancer subtype. For each patient enrolled, the use of TNFα antago-
nists [≥ one administration] and/or IMM at any time during the 
disease course, and not only during the 3  years’ follow-up, was 
reported and updated.
In this study, we aimed to confirm in a larger population find-
ings from our single-centre study,17 suggesting the role of IBD phe-
notype in determining the cancer risk. In our previous study, as in 
other studies17,20, UC extent was subgrouped into distal [rectum 
and sigmoid colon], left-sided [or subtotal: up to the left flexure], 
and pancolitis [or extensive]. In order to confirm our findings and 
to calculate the sample size on the basis of our preliminary study,17 
UC was subgrouped into distal, left-sided [subtotal], and extensive 
[pancolitis].17,20 In a separate analysis, UC was also subgrouped into 
proctitis, left-sided, and extensive.6,19 The accuracy of cancer inci-
dence was provided by the written histological analysis of cancers 
[including date at diagnosis].
IBD phenotypes were defined only at enrolment, as 
described.5,6,17,20 In order to estimate with good accuracy cancer inci-
dence in CD vs UC, the study involved only tertiary IBD centres 
and patients were assessed by experienced, senior, IBD-dedicated 
gastroenterologists, routinely following clinical practice guidelines 
and procedures in order to accurately assess: diagnosis of IBD, IBD 
phenotype, and malignancy diagnosis and classification.5,6,32 In 
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particular, the diagnosis of CD vs UC was defined on the basis of 
clinical, haematochemical, endoscopic, histological and radiological 
assessments, including colonoscopy with biopsies and small-bowel 
imaging (ie entero-magnetic resonance imaging [MRI], entero- 
computed tomography [CT] and/or small intestine contrast ultra-
sonography).5,6 The diagnosis and phenotype of IBD were assessed 
and eventually discussed before entry, and patients with unclassified 
or indeterminate IBD were not included in the study.
2.3. Statistical analysis
Calculation of the sample size should require the knowledge of the 
expected incidence of cancer not only in the general IBD population, 
but also in patients with different CD phenotypes and UC extent, with 
and without IS and/or anti-TNFα use. The risk of incident cancer 
when considering IBD phenotype, CD pattern, UC extent, and IMM 
use is undefined. Sample size calculation was therefore based on our 
study17 assessing the cancer risk in CD vs UC patients treated or not 
treated with IMM, subgrouped according to CD phenotype, and UC 
extent subgrouped as described.17 In our single-centre study, the inci-
dence of cancer in UC and CD was 2.8% and 5.5%, respectively.17 On 
the basis of this observation, we estimated that a minimum of 2001 
person-years of follow-up would be needed to have a statistical power 
of 80% and type I error probability of 0.05 not to reject the hypoth-
esis that CD-UC type relative risk is equal to 1.96. The frequency of 
incident cancer was therefore assessed in 44 619 IBD patients, includ-
ing 21 953 CD and 22 666 UC, with or without IS and anti-TNFα use.
Association between risks factors and cancer was investigated in 
a multivariate logistic regression analysis in IBD and, separately, in 
UC and CD. ORs [95% CI] were calculated. Risk factors for can-
cer in IBD included: IBD phenotype, CD pattern [B1, B2 vs B3],5,19 
IBD extent, and perianal disease [Y/N] in CD. Adjusted factors in 
CD and, separately, UC patients included: smoking [Y/N], disease-
related surgery [Y/N], age [≥ 40 vs < 40 years], IBD duration [≥10 
vs < 10 years], and IS and/or anti-TNFα [Y/N] used as mono- or 
combotherapy. A crude cumulative incidence of cancer in UC and 
CD was estimated in terms of rate per 1000 patients, during the 
3-year follow-up. All incident cancers/neoplasia were reported and 
defined. Results were expressed as median [range]. Among UC and 
CD patients, differences between cases and controls were assessed 
by the Wilcoxon test [non-parametric test for continuous variables], 
chi-square or Fisher’s test [categorical variables], as appropriate.
3. Results
3.1. Incidence of cancer
The analysis included 44 619 IBD [21 953 CD and 22 666 UC] 
patients. Incident cancer was observed in 174 IBD patients [IBD-K], 
including 99 CD [CD-K], and 75 UC [UC-K]. In IBD, the overall 
cumulative incidence of cancer was 3.9/1000 [174/44, 619 patients]. 
The cumulative incidence of cancer overall was significantly higher 
in CD at 4.5/1000 [99/21, 953 patients] than in UC at 3.3/1000 
[75/22, 666 patients]; p  =  0.042] [Figure  1]. As each of the 174 
IBD-K patients was matched with two IBD patients without can-
cer, controls included 348 IBD patients [IBD-C]: 198 CD-C and 
150 UC-C, without cancer. All the 522 IBD patients completed the 
3 years’ follow up. None of the 348 IBD-C showed cancer at entry 
according to the study protocol, and none of them developed cancer 
during the 3 years’ follow up.
3.2. Clinical characteristics
The IBD group [n = 522] included 174 patients with incident cancer 
(CD-K: n = 99, 57%; UC-K: n = 75, 43%; age 57 [17–85] years); 
and 348 matched IBD controls with no cancer (CD-C: n  =  198, 
57%; UC-C: n = 150, 43%; age 57 [15–87] years). Matched clini-
cal characteristics were comparable between CD and UC patients 
and controls [Table 1]. When considering unmatched characteristics, 
only the frequency of surgery was higher in UC-K than in UC-C 
[p = 0.0007]. The other variables, including CD and UC duration, 
were comparable between IBD patients with or without cancer 
[Table 1]. A comparable proportion of CD-K and CD-C showed per-
ianal disease [n = 25 [25.3%] vs 42 [21.2%], respectively, p = 0.43]. 
CD localisation was comparable between CD-K and CD-C (L1: 38 
[38%] vs 117 [40%]; L2: 16 [16%] vs 54 [18%]; L3: 39 [39%] vs 
115 [39%]; no recurrence: 1 [1%] vs 2 [2%]; others: 5 [5%] vs 7 
[2%]), respectively. At diagnosis of IBD, patients were younger in 
CD-K vs UC-K [p = 0.025], but not in CD-C vs UC-C [Table 1]. No 
differences were observed in terms of age at diagnosis of IBD, in CD 
and UC patients with or without cancer [CD-K vs CD-C and UC-K 
vs UC-C] [Table 1]. The frequency of smokers was higher in CD-C 
than in UC-C [p < 0.0001] and comparable between CD-K vs UC-K. 
At diagnosis of cancer, the age was lower in CD patients with a B1 
vs a B2 phenotype (47 [17–77] vs 59.5 [25–80]; p = 0.005, respec-
tively), whereas no differences were observed between CD patients 
with a B1 vs B3 (50 [20–84]; p = 0.29) or with a B3 vs B2 [p = 0.16]) 
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Figure 1. Incidence rates of cancer overall in patients with inflammatory bowel disease [IBD]: Crohn’s disease [CD], ulcerative colitis [UC]. The incidence rate of 
cancer in general was significantly higher in CD than in UC [p = 0.042].
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phenotype. Age at diagnosis of cancer was comparable between 
patients with distal, left-sided, or extensive UC (64 [35–83] vs 65 
[33–80] vs 59 [35–85]).
3.3. Use of immunomodulators
Current or past use of IS monotherapy was comparable between CD 
and UC patients with or without cancer [Table 1]. IS and/or TNFα 
antagonists were used in a higher proportion of CD vs UC patients 
[CD-K vs UC-K: p = 0.004; CD-C vs UC-C: p < 0.0001] [Table 1]. 
Anti-TNFα monotherapy was more frequent in CD-C than in UC-C 
[p < 0.001] and comparable between CD-K and UC-K. Combined 
IS and anti-TNFα treatment was also more frequent in CD than in 
UC [CD-K vs UC-K; p = 0.018; CD-C vs UC-C; p < 0.0001]. In CD 
patients, the median duration of IS treatment [months] at the end 
of the study was (27 [1–180]), showing no significant differences 
between patients with vs without cancer (CD-K vs CD-C: 36 [1–168] 
vs 24 [1–180], p = 0.4). In the UC group, the median duration of IS 
treatments was 24 [1–132] months, being comparable between cases 
and controls (UC-K vs UC-C: 30 [1–132] vs 24 [1–120]; p = 0.61). In 
the CD group, the median months of any anti-TNFα treatment dur-
ing the disease course was 27 [1–312], being comparable between 
patients with vs without cancer (CD-K vs CD-C: 21 [1–123] vs 32 
[3–312]; p = 0.15). In UC patients also the median months of any 
anti-TNFα treatment was comparable between cases and controls 
(UC-K vs UC-C: 11 [3–57] vs 7 [1–43]; p = 0.23; all UC patients: 
8 [1–57]). Further analysis regarding cancer and dose/duration of 
IMM will be investigated in a longer follow-up.
The median age at diagnosis of cancer did not differ between 
CD and UC patients with or without history of IS and/or anti-
TNFα use (IS: 57 [31–73] vs 52 [17–84] in CD; 53 [33–71] vs 
60 [35–85] in UC; anti-TNFα: 46 [24–74] vs 54 [17–84] in CD; 
59 [43–78] vs 59 [33–85] in UC; combined IS and anti-TNFα: 48 
[17-70] vs 55 [24–84] in CD; 56 [36–80] vs 59 [33–85] in UC; no 
IS, no anti-TNFα: 56 [25–84] vs 51[17–74] in CD; 61 [36–80] vs 
55 [33–80] in UC).
3.4. Characterization of incident cases of cancer
Cancer in the 174 IBD patients involved [Figure  2]: diges-
tive system [n  =  64; 36.8%], skin [n  =  23; 13.2%], urinary tract 
[n = 21;12.1%], lung [n = 15; 8.6%], breast [n = 14; 8.0%], genital 
tract [n = 12;6.9%], thyroid [n = 8;4.6%], lymphoma [n = 6; 3.5%], 
and others [≤ 2 cases] [n = 11; 6.3%] [Table 2]. The 64 cancers of 
the digestive system in IBD included [Figure  2]: colorectal cancer 
[CRC] [n = 43; 67.2%], small-bowel carcinoma [SBC][n = 8;12.5%], 
carcinoid [n = 3; 4.7%], cholangiocarcinoma [n = 3; 4.7%], anal car-
cinoma [n = 2; 3.1%], and others [n = 5; 7.8%]. Skin cancers in IBD 
[n = 23] included 9 NMSC [all basal cell carcinomas, BSC] [Table 3].
Lymphoma [four nonHodgkin, NHL, two Hodgkin, HL] occurred 
in six patients after the diagnosis of CD (six males, age at diagnosis 
of CD 38 [16–50]). In these six patients, the median age at diagno-
sis of lymphoma was 46 [28–62] and CD duration at diagnosis of 
lymphoma was 9 years [5–30]. Current or past use of both AZA and 
TNFα antagonists was reported in two of the six patients (Patient 
[Pt 1]: NHL, AZA monotherapy for 1 year, combined adalimumab 
for 2 years, CD diagnosed at 16 years, lymphoma at 28 years; Pt 
2: NHL, AZA for 21 months, combined adalimumab for 3 months, 
CD diagnosed at 18 years, lymphoma at 48 years). History of AZA 
monotherapy [5 years] was reported in one of the six patients [Pt 
3: NHL, CD diagnosed at 38, lymphoma at 62 years]. Any IMM 
was used by three patients [Pt 4: HL, stage IV, CD diagnosed at 38, 
lymphoma at 43 years; Pt 5: HL, CD diagnosed at 45, lymphoma at 
50 years; Pt. 6: NHL, CD diagnosed at 48, lymphoma at 54 years].
All eight SBC occurred in patients with stricturing CD (eight 
males, age 56 [40–68]), with current IMM [AZA] use in one 
patient. The median CD duration in these eight patients was 1 year 
[1–38][≤ 1  year in five patients; ≥ 13  years in three patients]. 
Cholangiocarcinoma occurred in three patients [one CD, two UC]: 
1.72% [3/174] of overall cancers and 4.7% [3/64] of cancers of the 
digestive system. Primary sclerosing cholangitis [PSC] was present in 
one of these three patients [UC, female, age 32, UC duration 9 years, 
AZA for 26 months, no anti-TNFα]. PSC was also diagnosed in two 
CD patients with CRC and no cholangiocarcinoma.
Table 1. Clinical characteristics of CD and UC patients with incident cancer [CD-K, UC-K], and of their matched CD and UC controls with no 
cancer [CD-C, UC-C], including matched* and unmatched variables [patients n = 150].
CD-K CD-C UC-K UC-C
Patients [n] 99 198 75 150
Age [years]* 55 [16–84] 54 [15–79] 61 [32–85] 60 [29–87]
Gender*
 Females [%] 47 [47%] 94 [47%] 32 [43%] 64 [43%]
 Males [%] 52 [53%] 104 [53%] 43 [57%] 86 [57%]
IBD duration [years] 13 [1–50] 12 [1–45] 12 [1–37] 13.5 [1–54]
Age at diagnosis of IBD 37 [6–80]a 39 [5–79] 42 [15–79] 42 [7–81]
Smoking habits [Y] 35 [35.4%] 78 [39.4%]b 17 [22.7%] 20 [13.3%]
Previous surgery [Y] 59 [59.6%]d 107 [54%]e 12 [16%]c 5 [3.3%]
Appendectomy [Y] 20 [20.2%]f 48 [24.2%]g 6 [8.0%] 13 [8.7%]
EIM [Y] 20 [27%] 49 [31%]h 10 [13.3%] 13 [8.7%]
IS [with no anti-TNFα] 20 [20.2%] 36 [18.2%] 15 [20%] 25 [16.7%]
Anti-TNFα [with no IS] 12 [12.1%] 23 [11.6%]i 4 [5.3%] 6 [4%]
IS with anti-TNFα 28 [28.3%]l 76 [38.4%]m 10 [13.3%] 21 [14.0%]
No IS, no anti-TNFα 39 [39.4%] 63 [31.8%] 46 [61.3%]n 98 [65.3%]o
IBD, inflammatory bowel disease; CD, Crohn’s disease; UC, ulcerative colitis; CD-K and UC-K, CD and UC patients with cancer, CD-C and UC-C, CD and UC 
patients with no cancer,;Y, yes; IS, thiopurines; EIM, extra-intestinal manifestations; TNF, tumour necrosis factor.
*Matched variables [not including matched phenotype].
a.p = 0.025 CD-K vs UC-K; bp < 0.0001 CD-C vs UC-C; cp < 0.0007 UC-K vs UC-C; d,ep < 0.0001 CD-K vs UC-K and CD-C vs UC-C; fp = 0.025 CD-K vs 
UC-K; gp < 0.0001 CD-C vs UC-C; hp < 0.0001 CD-C vs UC-C; ip < 0.001 CD-C vs UC-C; lp = 0.018 CD-K vs UC-K; mp < 0.0001 CD-C vs UC-C; np = 0.004 
CD-K vs UC-K; op < 0.001 CD-C vs UC-C.
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3.5. Incident cancer in CD vs UC
The frequency of cancer subtypes did not differ between CD [n = 99] 
and UC [n = 75] and involved: digestive system [35.3% vs 38.6%], 
urinary tract [9.1% vs 16%], skin [14.1% vs 12%], lung [17% 
vs 7%], breast [9% vs 6%], lymphoma [6 vs 0%], respectively 
[Table 2]. Among the 64 cancers involving the digestive system, 43 
[67.1%] were CRC [Figure 2]. The higher frequency of CRC in UC 
vs CD was at the limit of statistical significance (CRC/extracolonic 
cancers: 24/75 [32%] vs 19/99 [19.2%]; p = 0.052, respectively).
Lymphoma [n = 6] and SBC [n = 8] occurred only in CD. The fre-
quency of cancer involving the digestive system or the genitourinary 
tract vs other cancers did not differ between UC and CD [38.7% vs 
35.4%; 21.3% vs 17.2%, respectively; p = non-significant].
3.6. Risk factors for cancer
When considering CD phenotypes, among patients with penetrating 
disease there was a significantly higher proportion of patients with 
vs without cancer [B3 vs B1 and B2 in CD-K vs CD-C: 26/99 [26%] 
vs 30/198 [15%]; p  = 0.02][Figure 3a]. Conversely, a comparable 
proportion of patients with vs without cancer was observed within 
patients with a non-penetrating non-stricturing or with stricturing 
CD [Figure 3a].
In patients with extensive UC there was a significantly higher 
proportion of patients with vs without cancer (extensive UC vs oth-
ers: UC-K vs UC-C: 41/75 [55%] vs 51/149 [34%]) [Figure  3b]. 
The frequency of distal and left-sided UC was comparable between 
patients with vs without cancer [Figure  3b]. Comparable findings 
were observed when UC extent was subgrouped into proctitis, left-
sided, and extensive disease.
In CD, multivariate analysis adjusted for the reported variables 
[age at the latest visit, smoking, current or past treatments with 
IS and TNFα antagonists, disease-related surgery, CD duration] 
identified a penetrating vs non-penetrating non-stricturing CD as 
a significant risk factor for cancer overall (OR 2.33 [1.01–5.4]) 
[Figure  4a]. Current or past treatment with IS and anti-TNFα, 
considered as an adjustment factor, slightly increased the cancer 
risk (OR 1.95 [1.10–3.50]). Conversely, in a separate analysis, IS 
or anti-TNFα monotherapies were not identified as risk factors 
for cancer in CD (IS: OR 0.84 [0.45–1.59]; anti-TNFα: OR 0.95 
[0.44–2.12]). Multivariate analysis did not include CD location, 
as univariate analysis did not identify this variable as a risk factor 
for cancer.
In UC, multivariate analysis adjusted for the above reported vari-
ables identified extensive vs distal UC as a significant risk factor for 
any cancer (OR 2.52 [1.26–5.14]) [Figure 4b]. Comparable findings 
were observed when UC extent was subgrouped into proctitis, left-
sided, or extensive UC,19 as only extensive UC vs proctitis was a 
risk factor for cancer overall (OR 3.60 [1.13–14.6]). Disease-related 
surgery, considered as an adjustment factor, increased the cancer 
risk (OR 5.10 [1.73–17.15]) [Figure 4b]. Conversely, current or past 
treatment with IS and anti-TNFα did not increase the cancer risk in 
UC (combined IS and anti-TNFα: OR 1.10 [0.47–2.72]; IS: OR 0.68 
[0.32–1.48]; anti-TNFα: OR 0.99 [0.25–4.46]). In IBD, current or 
past treatment with IS and TNFα antagonists (OR 1.57 [1.00–2.49]) 
and disease-related surgery (OR 1.54 [1.02–2.33]) were identified 
as risk factors for any cancer. The same finding was not observed 
for IS or anti-TNFα monotherapy (OR 0.85 [0.53–1.36]; OR 0.96 
[0.50–1.89], respectively).
3.7. Risk factors for colorectal vs extracolonic cancers
As CRC represented almost one-fourth of cancers in IBD [24.7%], 
risk factors were also assessed for CRC and, separately, for extraco-
lonic cancers. Although the relatively small number of CRCs limited 
this analysis [CD n = 19; UC n = 24], perianal disease was identified 
as the only significant risk factor for CRC in CD (OR 3.86 [1.87–
12.5]) [Figure 4c].
Among the 19 CD patients with CRC, 8 also showed perianal 
disease. In these eight patients, CRC [all adenocarcinomas] involved 
the rectum in four [CRC adjacent to the fistula in one patient]. In 
CD, penetrating vs non-penetrating, non-stricturing behaviour 
and use of IS and TNFα antagonists were identified as risk factors 
for any cancer, but not for CRC (OR 0.37 [0.07–1.66]; OR 1.06 
[0.36–3.39]). Conversely, both variables increased the risk of extra-
colonic cancers [n = 80] (OR 3.9 [1.56–10.1]; OR 2.15 [1.16–4.1], 
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Figure 2. Characteristics of the 174 incident cases of cancer in patients with inflammatory bowel disease [IBD].
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respectively) [Figure 4c]. In CD, disease-related surgery was at the 
limit of the statistical significance as risk factor for extracolonic can-
cers (OR 1.54 [0.77–3.10]) [Figure 4c].
In UC, disease-related surgery was the only significant risk factor 
for CRC (OR 3.6 [1.0–12.0]) [Figure 4d]. Extensive vs distal UC and 
current or past treatment with combined IS and anti-TNFα were not 
identified as risk factors for CRC (OR 1.41 [0.54–3.86]; OR 0.68 
[0.20–2.8], respectively). Conversely, risk factors for extracolonic 
cancers in UC [n = 51] included extensive vs distal (OR 2.55 [1.15- 
5.9]) and left-sided vs distal disease (OR 2.6 [1.04–6.6]), surgery 
being at the limit of the statistical significance (OR 2.59 [0.84–7.58]) 
[Figure  4d. Comparable findings were observed when UC extent 
was subgrouped into proctitis, left-sided, and extensive disease, as 
disease-related surgery was identified as the only significant risk 
factor for CRC [OR 3.93 [1.12–12.47]]. Accordingly, risk factors 
for extracolonic cancers included extensive UC vs proctitis (OR 5.07 
[1.25–35.12]), whereas disease-related surgery was at the limit of the 
statistical significance (OR 2.59 [0.84–7.58]). In IBD, disease dura-
tion was a significant risk factor for CRC [n = 43] (OR 2.3 [1.06–
5.4]). Risk factors for extracolonic cancers in IBD [n = 131] included 
disease-related surgery (OR 2.09 [1.34–3.27]) and current or past 
treatment with combined IS and anti-TNFα (OR 1.65 [1.01–2.76]), 
but not with IS or anti-TNFα monotherapy (OR 1.21 [0.80–1.84]; 
OR 1.35 [0.86–2.14]).
In IBD, maintenance treatment with oral 5-aminosalicylic acid 
[5-ASA] was observed in 91.2% [476/522] of patients. The percent-
age of patients treated with 5-ASA was comparable between patients 
with vs without cancer ([IBD-K: 90.2% [157/174] vs IBD-C 91.6% 
[319/348]; CD-K vs CD-C: 83.8% [83/99] vs 86.8% [172/198]; 
UC-K vs UC-C: 98.6% [74/75] vs 98% [147/ 150]; p = non-signifi-
cant [n.s.]). No use of 5-ASA was observed in only 46/522 [8.81%] 
IBD patients: 17 patients with cancer [16 CD-K, 1 UC-K], 29 con-
trols [26 CD-C, 3 UC-C]. No CRC or SBC occurred in any of the 
patients never treated with 5-ASA.
3.8. Cancers involving the gastrointestinal system, 
the skin, and the urinary tract
Risk factors were also searched for incident cancers involving the 
digestive system [n  =  64], the skin [n  =  23], or the urinary tract 
[n = 21]. Although the few observed cases limited this analysis, no 
risk factors were detected for cancer of the digestive system (com-
bined IS and TNFα antagonists use: OR 1.40 [0.63–3.28]), urinary 
tract (combined IS and anti-TNFα use: OR 2.0 [0.64–8.8]; smoking: 
0.72 [0.22–1.95]), and skin (combined IS and anti-TNFα use: OR 
1.58 [0.46–6.3]).
Current and/or past history of IS and/or TNFα antagonists was 
observed in seven of the nine IBD patients with NMSC [IS in six], in 
five of the 11 patients with melanoma [anti-TNFα in four], in three 
of the six CD patients with lymphoma [IS in 1], in one of the eight 
CD patients with SBC, and in 11 of the 21 IBD patients with urinary 
tract cancer [Table 3].
3.9. Second and third incident cancer
During the 3 years’ follow-up, a second incident cancer occurred in 
11 of the 174 [6.32%] IBD patients: 6/99 [6.06%] with CD, 6/75 
[8%] with UC [Table  4]. Current or past use of IS and/or TNFα 
antagonists was reported in 5/11 IBD patients developing a second 
cancer. Among these 11 IBD patients with two incident cancers, two 
[18.1%] also developed a third cancer [2/174; 1.14%] [Table  4]. 
Both patients had a history of IS [n = 1] or anti-TNFα [n = 1] use. 
None of these 11 patients were treated with any IMM after the first 
cancer.
4. Discussion
The benefits when using immunomodulators in IBD currently appear 
to outweigh the cancer risk.1,2,5,6 Thiopurines and anti-TNFα treat-
ments may increase the cancer risk by interfering with the immune 
response towards tumour cells.1,5,6,21 In 1975, TNFα was described 
as an endotoxin causing necrosis of tumours, thus suggesting that 
blocking this cytokine may reduce the suppression of cancer cells.22 
TNFα antagonists have been reported to increase melanoma risk. 
13,14 Thiopurines increase the risk of Epstein-Barr virus-related 
lymphoma, B-cell lymphoma, HSTCL,1,23,24,25,26 and NMSC.1,3,4,27,28 
Table 2. Characterization of incident cancers in inflammatory bow-
el disease patients.
Cancer Crohn’s disease 
n = 99
Ulcerative colitis
n = 75
Digestive system [n = 64]
 CRC 19 24
 SBC 7 1 [pouch]
 Anal carcinoma 2 0
 Cholangiocarcinoma 1 2
 GIST 1 0
 Carcinoid 3 0
 Gastric 1 0
 Pancreatic 1 0
 HCC 0 1
 Oesophageal 0 1
Skin [n = 23]
 NMSC 7 2
 Melanoma 6 5
 Kaposi 0 2
 Keratoacanthoma 1 0
Urinary tract [n = 21]
 Renal 4 4
 Prostatic 5 6
 Bladder 0 2
Lung [n = 15] 7 8
Breast [n = 14] 7 7
Genital [n = 12]
 Ovary 1 1
 Uterine 5 2
 Testis 2 1
Thyroid [n = 8] 6 2
Lymphoma [n = 6] 6 0
Leukaemia [n = 1] 1 0
Multiple myeloma [n = 1] 0 1
Larynx [n = 1] 1 0
Tongue [n = 2] 0 2
Medulloblastoma [n = 1] 1 0
Suprarenal gland [n = 1] 1 0
Undifferentiated carcinoma 
metastatic [n = 1]
0 1
Carotid paraganglioma [n = 1] 1 0
Hibernoma [n = 1] 1 0
Pituitary adenoma [n = 1] 1 0
CRC, colorectal cancer, SBC, small-bowel cancer; NMSC, non-melanoma 
skin cancer; HCC, hepatocellular carcinoma; GIST, gastrointestinal stromal 
tumour.
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Table 3. Immunomodulators use in the 174 inflammatory bowel disease patients with incident cancer.
Cancer IS
monotherapy
[n = ]
Anti-TNFα
monotherapy
[n = ]
IS and anti-TNFα
[n = ]
No IS, no anti-TNFα
[n = ]
CRC 7 2 10 24
SBC 1 0 0 7
Anal carcinoma 0 0 2 0
Carcinoid 0 0 0 3
Cholangiocarcinoma 1 0 1 1
Oesophagus 0 0 0 1
GIST 0 0 0 1
Hepatocarcinoma 0 1 0 0
Pancreas 0 0 0 1
Breast 3 2 3 6
Lymphoma 1 0 2 3
Uterus 0 2 3 2
Ovary 1 0 0 1
Testis 1 0 1 1
Prostate 4 1 1 5
Kidney 2 1 2 3
Urinary bladder 1 0 0 1
Melanoma 1 2 2 6
NMSC 3 1 3 2
Kaposi 1 0 0 1
Keratoacantoma 0 0 1 0
Lung 7 0 1 7
Thyroid 1 1 3 3
Pituitary adenoma 0 1 0 0
Hibernoma 0 1 0 0
Larynx 0 0 0 1
Leukaemia 0 0 0 1
Tongue 0 0 0 2
Undifferentiated carcinoma metastatic 0 0 0 1
Medulloblastoma 0 0 1 0
Multiple myeloma 0 0 0 1
Carotid paraganglioma 0 0 1 0
Suprarenal gland 0 1 0 0
CRC, colorectal cancer; SBC, small-bowel cancer; NMSC, non-melanoma skin cancer; HCC, hepatocellular carcinoma; GIST:=, gastrointestinal stromal tumour; 
IS, thiopurines; TNF, tumour necrosis factor.
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Figure 3. Panel a. Crohn’s disease [CD], behaviour in patients with [CD-K: n = 99] or without [CD-C: n = 198] incident cancer. A higher proportion of CD patients 
with vs without cancer was observed in patients with penetrating disease [p = 0.02]. The frequency of patients with or without cancer did not significantly differ 
between patients with non-penetrating non-stricturing vs stricturing CD. Panel b. Ulcerative colitis [UC] extent in patients with distal, left-sided, and extensive 
disease in patients with [UC-K: n = 75] or without [UC-C: n = 150] incident cancer. A higher proportion of patients with vs without cancer was observed in patients 
with extensive UC [p = 0.003]. The frequencies of distal and left-sided UC were comparable between patients with vs without cancer. Comparable findings were 
observed when UC extent was subgrouped into extensive, left-sided, and proctitis.
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Table 4. Second and third incident cancer occurring in the cohort of 174 IBD patients during the 3 years’ follow-up: characterisation and 
immunomodulators use before cancer.
Immunomodulator use before the first cancer IS monotherapy
[n = ]
Anti-TNFα monotherapy
[n = ]
IS and anti-TNFα
[n = ]
No IS, no anti-TNFα
[n = ]
Second cancer
 CRC [n = 2] 0 1 0 1
 Testis [n = 1] 0 0 0 1
 Prostate [n = 1] 1 0 0 0
 Urinary bladder [n = 1] 0 1 0 0
 Kidney [n = 1] 0 1 0 0
 Breast [n = 1] 0 0 0 1
 Melanoma [n = 1] 0 0 0 1
 Thyroid [n = 1] 1 0 0 0
 Leukaemia [n = 1] 1 0 0 0
 Lung [n = 1] 0 0 0 1
Third cancer
 Pancreas [n = 1] 1 0 0 0
 Carcinoid [n = 1] 0 1 0 0
IBD, inflammatory bowel disease; CRC, colorectal cancer; IS, thiopurines; anti-TNFα, anti-tumour necrosis factor-α.
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Figure 4. Multivariate analysis assessing risk factors for cancer overall, for colorectal cancer [CRC] and for extracolonic cancers in patients with Crohn’s disease 
[CD] and ulcerative colitis [UC]. The following risk factors for cancer were identified. Panel a. In CD, penetrating vs non-penetrating non-stricturing CD for cancer 
overall: current or past treatment with thiopurines [IS] and tumour necrosis factor alpha [TNFα] antagonists slightly increased the risk for any cancer. Panel 
b.  In UC, disease-related surgery and extensive vs distal disease increased the overall cancer risk. Comparable findings were observed when UC extent was 
subgrouped into proctitis, left-sided, or extensive UC. Panel c. In CD, perianal disease was the only risk factor for colorectal cancer [CRC], whereas a penetrating vs 
non-penetrating non-stricturing behaviour and current or past treatment with thiopurines [IS] and TNFα antagonists were identified as risk factors for extracolonic 
cancers. Panel d. In UC, disease-related surgery was the only significant risk factor for CRC, whereas extensive vs distal and left-sided vs distal UC were identified 
as risk factors for extracolonic cancers. Comparable findings were observed when UC extent was subgrouped into proctitis, left-sided, and extensive disease.
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However, the absolute risk of these cancers is low,1,2,23,24,25,26,28 and 
a lower risk of CRC has been reported in patients with severe IBD 
treated with IMM.29,30,31 The overall cancer risk associated with IMM 
use in IBD has been extensively investigated.1,2,7,8,9,10,11,12,13,14,15,16, 
23,24,25,26,27,28 Conversely, evidence regarding the cancer risk associated 
with clinical characteristics of IBD vs the use of IMM treatments 
is lacking.17,18 We therefore investigated this issue in a prospective, 
multicentre, nested case-control study.
In our IBD population, the incidence of overall cancer was higher 
in CD than in UC, thus representing one of the main messages of 
the study. The low proportion of UC patients treated with IMM 
may be involved in this finding. A  single-centre study reported an 
overall excess risk of cancer in CD, but not in UC,18 in agreement 
with our retrospective study including a different IBD population.17 
Differences in terms of study design and populations may account 
for discrepant findings in this regard.1,32,33 Moreover, to the best of 
our knowledge, data from prospective, multicentre, nested case-con-
trol studies including incident cancers are currently lacking.1,32,33 To 
find whether IBD phenotype [CD vs UC] is a risk factor for cancer 
represented one of the aims of this study. Therefore, only patients 
with a definite diagnosis of UC or CD, according to current guide-
lines5,6 as judged by experienced, IBD-dedicated gastroenterologists 
referring to tertiary IBD centres, were enrolled. For proper assess-
ment, cases requiring revisions in order to confirm the diagnosis [CD 
vs UC] were excluded before entry. Although any diagnosis, includ-
ing of IBD [CD vs UC], may change over time, the methods applied 
provide evidence for an accurate diagnosis of CD vs UC in the tested 
population.
Multivariate analysis identified penetrating CD and extensive 
UC as risk factors for overall cancer and for extracolonic cancers, 
and this represented one of the main findings of the study. A higher 
frequency of penetrating CD and of extensive UC was observed 
in patients with vs without cancer, further supporting that severe 
inflammation may increase the cancer risk, as suggested by our retro-
spective study.17 Extensive UC is a known risk factor for CRC.1,29,32,33 
However, to the best of our knowledge, whether extensive UC and 
perforating CD may increase the risk of overall cancer and of extra-
colonic cancers is currently undefined.1,29,32,33 Comparable findings 
were observed when UC extent was subgrouped according to studies 
from our group17and others20 or to current guidelines.6,19 Although 
IBD phenotype may have changed during the study period, IBD phe-
notypes were defined only at enrolment. Indeed, we aimed to assess 
the role of IBD phenotype vs IMM in determining the cancer risk, 
and at entry all cases [IBD-K] had an incident cancer according to the 
inclusion criteria. The present study therefore evaluated risk factors 
for cancer in IBD, when considering IBD phenotype defined at time 
of the diagnosis of cancer. In particular, IBD phenotype was defined 
at enrolment when considering the entire disease history,5,6,17,20 and 
the median IBD duration of the tested population was quite long 
[≥ 12 years in both CD and UC groups]. However, IBD phenotype 
may have changed in subgroups of patients during the few addi-
tional 3 years of follow-up. This is not the case for patients with a 
perforating phenotype in CD or with pancolitis in UC [identified as 
the two IBD subgroups at higher cancer risk in the present study] 
at enrolment. Although a large population [> 46 000 patients] was 
considered, whether these findings may be extended to the general 
IBD population is being evaluated in a longer follow-up.
A comparable proportion of IBD patients with or without cancer 
showed a current or past treatment with IS and/or TNFα antago-
nists. However, TNFα antagonists were used in a higher proportion 
of CD vs UC patients without cancer. Although almost half of UC 
patients showed extensive disease, IMM were used in a low propor-
tion of patients.
Current or past combined treatment with IS and TNFα antago-
nists, considered as an adjustment variable, was identified as a risk 
factor for overall cancer in CD, although less significant than perfo-
rating CD. This observation, representing one of the main findings of 
the study, is in agreement with a recent study,34 although conflicting 
data are reported.1,32,33 As for IBD behaviour, differences in terms of 
study design and populations may account for the observed discrep-
ancies. In the present study, treatment with anti-TNFα and/or IMM 
at any time during the study period was considered, and treatments 
reported at time of enrolment were updated during the 3  years’ 
follow-up. These observations suggest the reliability of the reported 
findings. Combined IS and anti-TNFα treatment was also identified 
as a risk factor for overall cancer when data from CD and UC patients 
were grouped into one IBD group. Conversely, IS and/or anti-TNFα 
treatments did not appear to increase the cancer risk in UC, possibly 
due to the low proportion of treated patients. Whether IS monother-
apy may increase the overall cancer risk is debated.1,32,33,35 Several 
studies report no excess risk using IS,36 although the CESAME study, 
including NMSC, reported a higher risk.11 On the other hand, anti-
TNFα monotherapy currently appears not to increase the overall 
cancer risk.1,5,6,7,8,9,10,11,12,32,33,34 IMM are indicated in severe IBD, 
including perforating CD and extensive UC.5,6 As present findings 
identified these characteristics as risk factors for cancer, the possible 
relationship between IBD phenotypes and IMM in determining the 
cancer risk is being further defined in a longer follow-up.
In CD, perianal disease was identified as a risk factor for CRC, 
but not for overall cancer or for extracolonic cancers. Anal adenocar-
cinomas arising from perianal fistulas have been reported in CD,1,32 
but data regarding perianal CD as a risk factor for CRC are lacking. 
In our CD population, almost half of CRC occurred in perianal CD 
[8 out of 19 CRC, all adenocarcinomas], showing rectal involvement 
in half of cases [4 out of 8]. The limited number of cases did not 
allow the assessment of the role of the severity of inflammation vs 
the use of IMM in the occurrence of CRC in perianal CD. Whether 
perianal CD is a risk factor for CRC requires further investigations 
for proper surveillance.
IMM have been reported to reduce the risk of CRC in severe 
and extensive IBD colitis.1,29,32 In CD and in the whole group of 
IBD patients, treatment with IS and anti-TNFα was identified as a 
risk factor for overall cancer and for extracolonic cancers, but not 
for CRC. This finding further supports that controlling inflamma-
tion by using IMM may reduce the risk of colitis-associated CRC 
in IBD. A high proportion of IBD patients [91.2%] was on mainte-
nance treatment with 5-ASA, thus not allowing a proper assessment 
of the role of 5-ASA for preventing CRC and SBC. However, the 
observed incidence of these cancers was comparable to the general 
IBD population.32
Further supporting that the severity of IBD may increase the can-
cer risk, in UC not only extensive colitis, but also disease-related 
surgery were identified as risk factors for overall cancer and for 
CRC. Accordingly, disease-related surgery was observed in a higher 
proportion of UC patients with cancer [p  =  0.0007], whereas the 
same finding was not observed in CD, due to the high frequency of 
surgery in CD [> 50%]. In UC, disease-related surgery was associ-
ated with a 5-fold increased risk of overall cancer. This observation 
appeared mainly related to patients requiring colectomy for CRC, 
although disease-related surgery was at the limit of statistical signifi-
cance as risk factor for extracolonic cancers. Disease-related surgery 
was indeed a risk factor for extracolonic cancers in the whole group 
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of IBD patients, but not in CD and in UC groups separately consid-
ered. An explanation for this apparent discrepancy is that in both 
CD and UC, disease-related surgery as risk factor for extracolonic 
cancers was at the limit of the statistical significance. When data 
from CD and UC patients were grouped into one IBD group, both 
disease-related surgery and combined IS and anti-TNFα treatment 
were therefore identified as risk factors for extracolonic cancers. 
These findings further support a role for severe IBD often requiring 
surgery and IMM, in determining the cancer risk.
Age at the latest visit was not a significant risk factor, as cases and 
controls were matched for this variable of adjustment. IBD duration 
increased the CRC risk, as expected.1,6,29,32 The same finding was not 
observed when UC and CD were separately considered, due to the 
relatively limited number of cases [n = 19; n = 24, respectively].
Clinical characteristics and the cumulative incidence of can-
cer in IBD were comparable to the general IBD population,1,18,32,33 
thus supporting the reliability of our findings. This is further sug-
gested by the observation that IBD duration [not matched vari-
able] was comparable between cases and controls. Patients and 
controls were not matched for smoking nor for family history of 
cancer, although these may possibly be relevant for some types of 
malignancies. As data were prospectively recorded, these risk fac-
tors invariably changed several times during the 3 years’ follow-up. 
Therefore, an accurate and updated match for smoking and for 
family history of cancer appeared not to be guaranteed for each 
patient and control recruited from the 16 centres. This is particu-
larly true for incident cancers occurring in each family member of 
each patient and control during the 3 years’ follow-up. Supporting 
these considerations, to the best of our knowledge, data from pro-
spective multicentre studies assessing risk factors for incident can-
cer in IBD patients and controls matched for all these variables are 
lacking.1,2,7,8,9,10,11,12,13,14,15,16,17,18,23,24,25,26,27,28,29,30,32,33,34 However, the 
observed percentage of smokers did not differ between CD and UC 
cases and controls, matched for gender and age. The expected higher 
frequency of smokers in CD vs UC5,6 was significant only for patients 
without cancer [CD-C vs UC-C; p  < 0.0001]. This may suggest a 
role for smoking in determining the cancer risk in UC, although this 
risk factor was not statistically significant. The low proportion of 
both smokers and smoking-related cancers observed in our popula-
tion may account for this finding. Although no scheduled surveil-
lance protocols were planned at enrolment, routine clinical practice 
guidelines/consensus were followed by the referral IBD-dedicated, 
experienced gastroenterologist in each centre. However, as not 
scheduled at entry, a minority of patients may have not followed 
the surveillance programme [particularly for extra-colonic cancers]. 
Nevertheless, the observation that all patients concluded the follow-
up at 3  years and that detailed information of characteristics of 
cancer were timely available for all patients, suggests good compli-
ance of the study population and reliability of the reported findings. 
A  high frequency of recurrent cancer was observed, in agreement 
with recent observations.37,38 thus representing one of the new mes-
sages of our study.
Although a large IBD population was considered, the number 
of incident cancers [n  = 174] allowed only the assessment of risk 
factors for cancer overall, for CRC, and for extracolonic cancers. 
Some of the observed associations for the overall population in 
contrast to the individual subtypes of IBD [CD or UC] may indeed 
be related to the small number of incident cases of cancer in the 
subtypes and to the relatively short period of both observation and 
IBD duration. However, in both CD and UC groups, the median 
IBD duration appeared not short [from 12 to 13.5 years], although 
showing wide inter-individual variations [from 1 to 54 years]. Risk 
factors for specific cancer subtypes, excluded from the aims of the 
study, are being assessed in a longer follow-up. Nevertheless, the 
more frequent cancers involved the digestive system, the skin, and 
the urinary tract, supporting recent studies.35 IS were used by almost 
half [11 out of 21] of IBD patients with urinary tract cancer, recently 
associated with IS use.35 SBC and lymphoma were observed only 
in CD, and CRC was the most frequent cancer of the digestive sys-
tem, as expected.1,6,29,30,31,32,33 CRC and SBC represented more than 
two-thirds of cancers, supporting the role of chronic inflammation 
in these cancers. SBC developed only in small-bowel CD, showing 
a high frequency [7.07%], thus supporting a role for the sequence 
‘uncontrolled inflammation-dysplasia-cancer’ not only in CRC, but 
also in SBC.28,39 This is also suggested by the finding that, despite 
the small sample, seven out of eight CD patients with SBC never 
received IS or TNFα antagonists. Conversely, although the incidence 
of SBC was at least equivalent to that of lymphoma, half of lym-
phomas were treated with IS or anti-TNFα [and still more in some 
extracolonic cancers, principally NMSC]. SBC was diagnosed either 
at CD onset or after a long history of stricturing CD. Despite the 
small sample, these preliminary findings suggest that both refractory/
recurrent obstructions at CD onset and a long history of stricturing 
small-bowel CD may represent risk factors for SBC even in patients 
never treated with IMM.
The present prospective, multicentre, nested case-control study 
supports that penetrating CD and extensive UC represent significant 
risk factors for cancer in general. In the tested IBD population, the 
cumulative incidence of cancer was higher in CD than in UC, whereas 
present or past treatments with IS and anti-TNFα, considered as an 
adjustment factor, slightly increased the risk of overall cancer and 
of extracolonic cancers in CD. On the other hand, the risk of CRC 
in CD was not increased by IS and TNFα antagonists, thus support-
ing that controlling severe inflammation by using IMM may reduce 
the risk of CRC in IBD.1,29,30,31,32,33 These findings suggest that IBD 
patients showing an aggressive course associated with severe and 
diffuse lesions, as observed in perforating CD and in extensive UC, 
may bear an increased overall cancer risk. Clinical characteristics of 
IBD should be considered among risk factors for cancer in general, 
particularly in young patients with perforating CD or extensive UC, 
most often requiring immunomodulators.
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